We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine (MP-12)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00415051
First Posted: December 22, 2006
Last Update Posted: May 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
U.S. Army Medical Research and Materiel Command
December 21, 2006
December 22, 2006
December 6, 2016
February 1, 2017
May 19, 2017
August 2006
May 2008   (Final data collection date for primary outcome measure)
Safety as Measured by the Number of Adverse Events [ Time Frame: up to 1 year ]
AE's will be assessed through study completion. Safety will be evaluated by recording the frequency of clinical reactions to the vaccine and by measuring complete blood counts and selected serum biochemistry (enzyme) values, rates of hospitalizations, and rates of lost duty/work time overall and by gender.
Not Provided
Complete list of historical versions of study NCT00415051 on ClinicalTrials.gov Archive Site
  • Immune Response Assessed by Measuring Days to Peak Response for PRNT80 Antibodies to RVF Virus [ Time Frame: Days 0, 1, 2, 3, 7, 10, 14 and 28, Months 3, 6 and 12 ]
    Immune response will be assessed by measuring days to peak response for PRNT80 antibodies to RVF virus
  • Immune Response Assessed by Measuring Days to Peak Response for (PRNT50) RVP MP-12 Vaccine [ Time Frame: Days 0, 1, 2, 3, 7, 10, 14 and 28, Months 3, 6 and 12 ]
    Immune response will be assessed by measuring days to peak response for PRNT50 antibodies to RVF virus
  • Genetic Stability - Characterize Viral Isolate (Plasma) Frequency [ Time Frame: Days 0-14 ]
    In vitro systems will be used to evaluate genetic stability (examining viremia levels in plasma by direct plaque assay techniques or by blind passage of plasma on Vero cells and sequencing the ribonucleic acid (RNA) and comparing these findings with those from the vaccine virus inoculum).
Not Provided
Not Provided
Not Provided
 
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study
This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.
Rift Valley Fever (RVF) is a mosquito-borne disease in Africa that affects both humans and animals. The disease poses a significant endemic disease threat, and the etiologic agent (RVF virus) possesses physical and biochemical characteristics that have resulted in its classification as a Category A Agent. Historically, this disease was confined to Africa. In September 2000, however, RVF appeared in the western part of the Kingdom of Saudi Arabia (843 cases with 114 deaths) and in Yemen (1,087 suspected cases with 121 deaths). It is thought that Rift Valley fever was introduced into this new geographic area through importation of infected livestock from Djibouti. Mosquito transmission has been subsequently demonstrated in these areas, suggesting that the disease may have become permanently established. A safe and effective RVF vaccine capable of inducing protective immunity after a single injection is urgently needed. Currently, no drug is available that will alter the course of the disease in humans or animals, nor is any licensed vaccine for RVF approved for human use. This protocol is an open-label, Phase II study to assess the safety, immunogenicity and genetic stability of RVF MP-12 vaccine in humans. The objectives of this study are to collect safety and immunogenicity data for an intramuscular (IM) injection of live, attenuated, mutagenized RVF 12th mutagenesis passage (MP-12) vaccine and characterize isolates of the Rift Valley fever (RVF) MP-12 vaccine recovered from blood of vaccinated volunteers using in vitro systems to evaluate genetic stability. A total of 20 volunteers will be recruited from among military and civilian persons at and around USAMRIID and from the general population in and around Frederick, Maryland, who expect to remain in the area for the duration of the study. Volunteers will be vaccinated with undiluted RVF MP-12 vaccine. Safety will be evaluated by recording the frequency and severity of clinical reactions to the vaccine, as well as by measuring complete blood counts and selected serum biochemistry (enzyme) values. Immunogenicity will be evaluated by measuring 80% plaque reduction neutralization (PRNT80) antibodies to RVF virus for periods up to 1 year following vaccination. Genetic stability of the vaccine will be evaluated by examining isolates recovered from blood of vaccinated volunteers by molecular sequencing techniques, and comparing these findings with those from the vaccine virus inoculum. Subjects will participate in the study for up to 1 year.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Rift Valley Fever
Biological: RVF MP-12
Administer 1 ml SQ
Experimental: Single Group Assignment
RVF MP-12
Intervention: Biological: RVF MP-12
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
May 2009
May 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Between 18 and 50 years old
  • Free of chronic medical conditions requiring ongoing therapy and in general good health as determined by a physician investigator
  • Have a current (within 30 days of scheduled blood donation for this study) complete blood (cell) count (CBC) to include a Hct and Hgb that show no evidence of anemia, and total white blood cell with differential platelet counts that are within normal range, as well as hepatic enzyme (AST, ALT, LDH) values that are within normal laboratory ranges
  • Negative human immunodeficiency virus (HIV) antibody test within 3 months preceding vaccination
  • No evidence of pre-existing liver disease or current infection with Hepatitis A, B, or C virus as determined by serology
  • No evidence for pre-existing eye disease, as determined by fundoscopic/slit lamp examination by the study ophthalmologist other than refractory changes
  • No evidence by history or serologic testing for previous infection with RVF virus or RVF vaccine
  • Subjects must agree to refrain from intimate contact (sexual activity), or use barrier contraception (e.g., condoms), for the 2-week period following vaccination
  • Females of child-bearing potential must have a negative serum pregnancy test on screening and the morning of vaccination prior to receipt of the vaccine and must agree to use a highly effective method of birth control during the first 3 months following receipt of the MP-12 vaccine. A highly effective method of birth control is defined as one with a failure rate of less than 1% per year. Acceptable birth control methods that meet this criterion include hormonal implants and injectables (Norplant, Dep-Provera, Lunelle, and Etonogestrel); combined oral contraceptives; the intrauterine devices (IUDs) Copper T (380-A) or Mirena (Levonorgestrel Intrauterine System); female sterilization (tubal ligation); sexual abstinence; or a vasectomized partner.
  • Subjects must be medically cleared for participation by an investigator
  • Subjects must expect to remain in the area for the duration of the study
  • Volunteer must sign an approved informed consent
  • Volunteer must be willing to return for all follow-up visits including a post-vaccination ophthalmologic visit
  • Volunteer must be willing to refrain from excessive (more than individual's normal routine) exercise for a period of at least 2 weeks prior to and following vaccination
  • Volunteer must be willing to abstain from drinking alcoholic beverages for a period of at least 2 weeks prior to and following vaccination. Volunteer must not be a "weekend" drinker or normally drink more than 2 drinks a day if male or 1 drink a day if female.
  • Volunteer must agree to report any adverse event (AE) that may or may not be associated with administration of the test article during their participation in the study.

Exclusion Criteria:

  • History or evidence of liver disease/abnormality
  • History of pre-existing thymic disease or thymic dysfunction (any cellular immune or antibody disorders)
  • Be taking any medication, prescription or non-prescription (excluding dietary supplements), on a regular basis with the exception of contraceptive pills. This includes the regular use of statins, non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressive agents, antivirals, topical steroidal creams, and nasal sprays. Conditions requiring intermittent medications and other decisions regarding eligibility due to medication use will be deferred to physician investigators.
  • Elevation above the upper limit of laboratory normal values in liver enzymes, or history of unexplained elevation in liver enzymes
  • History or evidence of eye disease (excluding changes in refraction and strabismus)
  • Abnormal clinical lab results indicating evidence of anemia, immunosuppression, or immune deficiency disease
  • Have donated 1 unit (500 cc) or more of blood for any reason during the 2 months (56 days) preceding administration of the vaccine (as assessed by query)
  • Plan to donate blood within 1 year following receipt of the vaccine
  • History or evidence of previous infection with RVF or vaccination against RVF
  • Any known allergies to components of the vaccine: Human serum albumin (stabilizer), Sol-U-Pro, Neomycin (antibiotic), sorbitol, L-proline, L-arginine, monosodium glutamate (MSG), or Urea
  • Administration of another vaccine within 4 weeks of RVF MP-12 vaccination
  • "Weekend" drinkers, males who drink more than 2 drinks a day and females who drink more than 1 drink a day, will be excluded
  • Individuals who plan to start a new exercise program within two weeks of vaccination (either two weeks prior to or two weeks following vaccination) will be excluded. Individuals who are already on a regular exercise program and who have normal transaminase levels will not be excluded but will be advised not to increase their level of activity for a period of one month (for two weeks prior to until two weeks after vaccination). Individuals who do not exercise regularly and who participate in this study will be advised not to embark on an exercise program for the same time period.
  • Volunteers will be cautioned against salivary contact and contact with infants, children under the age of 8 years, adults over the age of 64 years, and anyone who is immunocompromised or in poor health. Volunteers who feel unable to comply with these restrictions will be excluded from the study.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00415051
FY04-33, Log A-13698
No
Not Provided
Plan to Share IPD: Undecided
U.S. Army Medical Research and Materiel Command
U.S. Army Medical Research and Materiel Command
Not Provided
Principal Investigator: Phillip Pittman, MD USAMRIID Medical Division
U.S. Army Medical Research and Materiel Command
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP